Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

And for Wegovy’s Next Trick, Full-Blown Cardiovascular Benefit Outside Diabetes

PHILADELPHIA — An enormous swath of Americans can be expected to get secondary cardiovascular prevention benefits from weekly semaglutide (Wegovy) injections based on the SELECT

November 12, 2023

AHA scientific statement: Advances and challenges in AI applications for cardiovascular medicine

Artificial intelligence (AI) may transform cardiovascular medicine. For now, though, many challenges remain, and few AI tools have been proven to improve care, according to

February 28, 2024

Aspirin adherence after heart attack linked to lower risk of recurrent heart attack, stroke, death

Heart attack patients who do not take daily aspirin have an elevated likelihood of recurrent myocardial infarction, stroke or death compared with those who consistently

August 22, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.